AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2021
145
Period ended Dec 31, 2021
Change on a year earlier
+16.0%
125 in FY2020
History
4 years
Since FY2018
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 145 | +16.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 125 | +34.4% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 93 | +745.5% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 11 | – | Form 10-K (filed 2021-02-19) ↗ |
Breakdown
What makes up orilissa/oriahnn [legacy through fy21] — worldwide net revenues ($m)
- Orilissa/Oriahnn [legacy through FY21] — U.S. net revenues ($M)139 · FY2021
- Orilissa/Oriahnn [legacy through FY21] — International net revenues ($M)6 · FY2021
- Orilissa/Oriahnn [legacy through FY21] — Worldwide reported growth YoY (%)16.7% · FY2021
- Orilissa/Oriahnn [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%)47.6% · FY2021
Cite this data
StockData. (2026). AbbVie Orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M) ($M), annual FY2018–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/orilissa_oriahnn_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.